Cencora Stock Surges 8.1%, With A 7-Day Winning Spree
Cencora (COR) stock hit day 7 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 8.1% return. The company has gained about $5.3 Bil in value over the last 7 days, with its current market capitalization at about $71 Bil. The stock remains 63.5% above its value at the end of 2024. This compares with year-to-date returns of 16.4% for the S&P 500.
Cencora’s recent streak surged following a Q4 earnings beat and a 9% dividend hike, signaling strong financial health. Analysts quickly upgraded price targets, highlighting robust specialty pharmaceutical growth and strategic network investments bolstering its U.S. healthcare segment. For quick background: COR provides sourcing and distribution of pharmaceutical products, operating since 2001 and headquartered in Conshohocken, Pennsylvania.
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades. Our take: There is a near-equal mix of good and bad in COR stock given its overall Moderate operating performance and financial condition. But keeping in mind its High valuation, we think that the stock is Unattractive. Deep dive with Buy or Sell COR.
Individual stocks can soar or tank but one thing matters: staying invested. High Quality Portfolio helps you do that.
Comparing COR Stock Returns With The S&P 500
The following table summarizes the return for COR stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | COR | S&P 500 |
|---|---|---|
| 1D | 0.1% | 0.2% |
| 7D (Current Streak) | 8.1% | 0.1% |
| 1M (21D) | 15.2% | 2.9% |
| 3M (63D) | 25.7% | 5.9% |
| YTD 2025 | 63.5% | 16.4% |
| 2024 | 10.4% | 23.3% |
| 2023 | 25.3% | 24.2% |
| 2022 | 26.7% | -19.4% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 149 S&P constituents with 3 days or more of consecutive gains and 7 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 92 | 1 |
| 4D | 26 | 4 |
| 5D | 17 | 1 |
| 6D | 8 | 0 |
| 7D or more | 6 | 1 |
| Total >=3 D | 149 | 7 |
Key Financials for Cencora (COR)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $262.2 Bil | $294.0 Bil |
| Operating Income | $2.7 Bil | $3.2 Bil |
| Net Income | $1.7 Bil | $1.5 Bil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $75.5 Bil | $80.7 Bil |
| Operating Income | $1.2 Bil | $980.2 Mil |
| Net Income | $717.9 Mil | $687.4 Mil |
While COR stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.